Thus, therapeutic strategies for SHH-pathway-dependent cancers primarily aim at inhibiting the components of the SHH pathway, including the SHH ligand itself as well as SMO and GLI proteins [103,104,105,106]. This evidence concerns the gene SHH and cancer.